Ann Gastroenterol. 2017;30(2):209-216. doi: 10.20524/aog.2016.0107. Epub 2016 Dec 01.
Serum levels of vascular endothelial growth factor in non-alcoholic fatty liver disease.
Annals of gastroenterology
Maria-Vasiliki Papageorgiou, Emilia Hadziyannis, Dina Tiniakos, Anastasia Georgiou, Aikaterini Margariti, Athanasios Kostas, George V Papatheodoridis
Affiliations
Affiliations
- Academic Department of Gastroenterology, Medical School, National and Kapodistrian University of Athens, Laiko General Hospital (Maria-Vasiliki Papageorgiou, Anastasia Georgiou, Athanasios Kostas, George V. Papatheodoridis).
- 2nd Academic Department of Internal Medicine, Medical School, National and Kapodistrian University of Athens, Hippokration General Hospital (Emilia Hadziyannis, Aikaterini Margariti).
- Laboratory of Histology & Embryology, Medical School, National and Kapodistrian University of Athens (Dina Tiniakos), Athens, Greece.
PMID: 28243042
PMCID: PMC5320034 DOI: 10.20524/aog.2016.0107
Abstract
BACKGROUND: This study aimed to assess the significance of serum levels of vascular endothelial growth factor (VEGF) in non-alcoholic fatty liver disease (NAFLD).
METHODS: Sixty-seven consecutive NAFLD patients and 47 healthy controls who visited our liver clinics between May 2008 and December 2010 were included. The NAFLD diagnosis required elevated alanine aminotransferase and/or gamma-glutamyl transpeptidase levels, evidence of hepatic steatosis on ultrasound and/or liver histology, and exclusion of other causes of liver injury. Serum VEGF levels were determined by an enzyme immunoassay. Liver biopsy was obtained in 34 NAFLD patients. Histological lesions were scored by a liver histopathologist.
RESULTS: Serum VEGF levels tended to be lower in matched NAFLD patients than in healthy controls (296±146 vs. 365±186 pg/mL, P=0.092); levels in patients with non-alcoholic steatohepatitis (NASH) also tended to be lower than in those with simple fatty liver (FL) (279±149 vs. 359±190 pg/mL, P=0.095); while VEGF levels were significantly lower in NASH patients than in healthy controls (279±149 vs. 365±186 pg/mL, P=0.041). VEGF levels offered poor predictability for the differentiation between NAFLD patients and controls or between NASH and FL patients. However, patients with high VEGF levels (≥300 pg/mL) were significantly more likely to have FL, either in the total NAFLD population (67% vs. 35%, P=0.019) or in the 34 NAFLD patients with liver biopsy (57% vs. 15%, P=0.023), while those with high VEGF levels also had a significantly lower mean fibrosis score (0.7±0.9 vs. 1.6±1.0, P=0.017).
CONCLUSION: Our data suggest that serum VEGF levels are equally high in healthy controls and in patients with simple fatty liver, but tend to decrease when NASH develops.
Keywords: Nonalcoholic fatty liver disease; angiogenesis markers; nonalcoholic steatohepatitis; vascular endothelial growth factor; vascular endothelial growth factor receptors
Conflict of interest statement
Conflict of interest: None
References
- Am J Gastroenterol. 1999 Sep;94(9):2467-74 - PubMed
- Hepatology. 2011 Sep 2;54(3):1082-90 - PubMed
- Aliment Pharmacol Ther. 2005 Jul 1;22(1):23-30 - PubMed
- Semin Diagn Pathol. 2005 Nov;22(4):330-8 - PubMed
- Hepatology. 2005 Sep;42(3):696-701 - PubMed
- Gastroenterology. 2016 Jun;150(8):1769-77 - PubMed
- Ann Hepatol. 2007 Jul-Sep;6(3):170-3 - PubMed
- Annu Rev Pathol. 2016 May 23;11:451-96 - PubMed
- Hepatology. 2004 Aug;40(2):386-93 - PubMed
- Hepatol Int. 2013 Mar;7(1):4-12 - PubMed
- Hepatology. 2009 Mar;49(3):809-20 - PubMed
- J Hepatol. 2004 Nov;41(5):864-80 - PubMed
- World J Hepatol. 2015 Mar 27;7(3):377-91 - PubMed
- World J Gastroenterol. 2014 Jul 21;20(27):9026-37 - PubMed
- Cytokine. 2012 Aug;59(2):442-9 - PubMed
- Hepatology. 2004 May;39(5):1185-95 - PubMed
- Am J Gastroenterol. 2003 Sep;98(9):2042-7 - PubMed
- Liver Int. 2011 Feb;31(2):146-62 - PubMed
- Clin Liver Dis. 2007 Feb;11(1):75-104, ix - PubMed
- Hepatology. 2005 Jun;41(6):1313-21 - PubMed
- J Hepatol. 2005 Jan;42(1):7-11 - PubMed
- World J Gastroenterol. 2009 Nov 7;15(41):5193-9 - PubMed
- JAMA. 2001 May 16;285(19):2486-97 - PubMed
- J Hepatol. 2011 Jun;54(6):1224-9 - PubMed
- Am J Surg Pathol. 2011 Sep;35(9):1400-4 - PubMed
- World J Gastroenterol. 2012 Feb 28;18(8):727-35 - PubMed
- Hepatology. 1997 Jan;25(1):229-34 - PubMed
- Hepatol Int. 2013 Mar;7(1):233-40 - PubMed
- J Clin Gastroenterol. 2006 Mar;40 Suppl 1:S17-29 - PubMed
- Eur J Gastroenterol Hepatol. 2010 Jun;22(6):643-50 - PubMed
- Arch Med Res. 2011 Jan;42(1):38-43 - PubMed
- Hepatology. 2006 Oct;44(4):983-91 - PubMed
- Histopathology. 2006 Nov;49(5):450-65 - PubMed
- Semin Liver Dis. 2015 Aug;35(3):221-35 - PubMed
- World J Gastroenterol. 2008 Feb 14;14(6):831-44 - PubMed
- World J Gastroenterol. 2005 Feb 21;11(7):960-3 - PubMed
- Ann Hepatol. 2009;8 Suppl 1:S4-8 - PubMed
- Proc Natl Acad Sci U S A. 2012 Apr 10;109(15):5874-9 - PubMed
- Rev Esp Enferm Dig. 2008 Apr;100(4):212-8 - PubMed
- Liver Int. 2014 Apr;34(4):521-34 - PubMed
- Hepatol Res. 2013 Nov;43(11):1241-50 - PubMed
- Eur J Gastroenterol Hepatol. 2009 May;21(5):504-11 - PubMed
- Gastroenterology. 2005 Jun;128(7):1898-906 - PubMed
Publication Types